+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Imaging beta-amyloid burden in aging and dementia.

      Aged, Aged, 80 and over, Aging, metabolism, pathology, Alzheimer Disease, radionuclide imaging, Amyloid beta-Peptides, analysis, Aniline Compounds, diagnostic use, Apolipoproteins E, genetics, Brain Chemistry, Carbon Radioisotopes, Cognition Disorders, Dementia, Female, Gyrus Cinguli, chemistry, Humans, Lewy Body Disease, Magnetic Resonance Imaging, Male, Middle Aged, Neocortex, Radiopharmaceuticals, Thiazoles

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          To compare brain beta-amyloid (Abeta) burden measured with [(11)C]Pittsburgh Compound B (PIB) PET in normal aging, Alzheimer disease (AD), and other dementias. Thirty-three subjects with dementia (17 AD, 10 dementia with Lewy bodies [DLB], 6 frontotemporal dementia [FTD]), 9 subjects with mild cognitive impairment (MCI), and 27 age-matched healthy control subjects (HCs) were studied. Abeta burden was quantified using PIB distribution volume ratio. Cortical PIB binding was markedly elevated in every AD subject regardless of disease severity, generally lower and more variable in DLB, and absent in FTD, whereas subjects with MCI presented either an "AD-like" (60%) or normal pattern. Binding was greatest in the precuneus/posterior cingulate, frontal cortex, and caudate nuclei, followed by lateral temporal and parietal cortex. Six HCs (22%) showed cortical uptake despite normal neuropsychological scores. PIB binding did not correlate with dementia severity in AD or DLB but was higher in subjects with an APOE-epsilon4 allele. In DLB, binding correlated inversely with the interval from onset of cognitive impairment to diagnosis. Pittsburgh Compound B PET findings match histopathologic reports of beta-amyloid (Abeta) distribution in aging and dementia. Noninvasive longitudinal studies to better understand the role of amyloid deposition in the course of neurodegeneration and to determine if Abeta deposition in nondemented subjects is preclinical AD are now feasible. Our findings also suggest that Abeta may influence the development of dementia with Lewy bodies, and therefore strategies to reduce Abeta may benefit this condition.

          Related collections

          Author and article information


          Comment on this article